Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host

Journal of Lipid Research

Volumn 45, Issue 7, 2004, Pages 1169-1196

  Khovidhunkit, Weerapan ^a   Kim, Min Sun ^b   Memon, Riaz A ^b   Shigenaga, Judy K ^b   Moser, Arthur H ^b   Feingold, Kenneth R ^b   Grunfeld, Carl ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute phase response; Atherosclerosis; Cytokine; Endotoxin; Lipopolysaccharide

Indexed keywords

APOLIPOPROTEIN E; CERAMIDE; CYTOKINE; ENDOTOXIN; FARNESOID X RECEPTOR; GLUCOSYLCERAMIDE; HIGH DENSITY LIPOPROTEIN; HORMONE RECEPTOR; LIPOPOLYSACCHARIDE; LIPOPROTEIN LIPASE; LIPOPROTEIN RECEPTOR; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID X RECEPTOR; SPHINGOMYELIN; VERY LOW DENSITY LIPOPROTEIN;

ACUTE PHASE RESPONSE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HOST CELL; HYPERCHOLESTEROLEMIA; INFECTION; INFLAMMATION; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3042606551     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.R300019-JLR200     Document Type: Review

References (379)

1. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340: 448-454.
2. Yoo, J. Y., and S. Desiderio. 2003. Innate and acquired immunity intersect in a global view of the acute-phase response. Proc. Natl. Acad. Sci. USA. 100: 1157-1162.
3. Okusawa, S., J. A. Gelfand, T. Ikejima, R. J. Connolly, and C. A. Dinarello. 1988. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81: 1162-1172.
4. Yokota, T., N. Arai, J. de Vries, H. Spits, J. Banchereau, A. Zlotnik, D. Rennick, M. Howard, Y. Takebe, S. Miyatake, F. Lee, and K. Arai. 1988. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells. Immunol. Rev. 102: 137-187.
5. de Waal Malefyt, R., H. Yssel, M. G. Roncarolo, H. Spits, and J. E. de Vries. 1992. Interleukin-10. Curr. Opin. Immunol. 4: 314-320.
6. Pickup, J. C., and M. A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 41: 1241-1248.
7. Pradhan, A. D., and P. M. Ridker. 2002. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur. Heart J. 23: 831-834.
8. Huerta, M. G., and J. L. Nadler. 2002. Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. Curr. Diab. Rep. 2: 396-402.
9. Grimble, R. F. 2002. Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care. 5: 551-559.
10. Yudkin, J. S., M. Kumari, S. E. Humphries, and V. Mohamed-Ali. 2000. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 148: 209-214.
11. Sharma, R., F. O. Al-Nasser, and S. D. Anker. 2001. The importance of tumor necrosis factor and lipoproteins in the pathogenesis of chronic heart failure. Heart Fail. Monit. 2: 42-47.
12. Young, J. L., P. Libby, and U. Schonbeck. 2002. Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 88: 554-567.
13. Hardardóttir, I., C. Grunfeld, and K. R. Feingold. 1995. Effects of endotoxin on lipid metabolism. Biochem. Soc. Trans. 23: 1013-1018.
14. Khovidhunkit, W., R. A. Memon, K. R. Feingold, and C. Grunfeld. 2000. Infection and inflammation-induced proatherogenic changes of lipoproteins. J. Infect. Dis. 181 (Suppl. 3): 462-472.
15. Gallin, J. I., D. Kaye, and W. M. O'Leary. 1969. Serum lipids in infection. N. Engl. J. Med. 281: 1081-1086.
16. Sammalkorpi, K., V. Valtonen, Y. Kerttula, E. Nikkila, and M. R. Taskinen. 1988. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 37: 859-865.
17. Grunfeld, C., M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold. 1992. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74: 1045-1052.
18. Fiser, R. H., T. D. Shultz, R. B. Rindsig, and W. R. Beisel. 1973. Alterations in plasma and brain lipid metabolism during endotoxemia in the neonatal rat. Biol. Neonate. 22: 155-160.
19. Kaufmann, R. L., C. F. Matson, and W. R. Beisel. 1976. Hypertriglyceridemia produced by endotoxin: role of impaired triglyceride disposal mechanisms. J. Infect. Dis. 133: 548-555.
20. Sakaguchi, O., and S. Sakaguchi. 1979. Alterations of lipid metabolism in mice injected with endotoxin. Microbiol. Immunol. 23: 71-85.
21. Scholl, R. A., C. H. Lang, and G. J. Bagby. 1984. Hypertriglyceridemia and its relation to tissue lipoprotein lipase activity in endotoxemic, Escherichia coli bacteremic, and polymicrobial septic rats. J. Surg. Res. 37: 394-401.
22. Gaal, D., T. Kremmer, Z. Balint, L. Holczinger, L. Bertok, and A. Nowotny. 1984. Effects of bacterial endotoxins and their detoxified derivatives on serum and liver lipids in mice. Toxicol. Appl. Pharmacol. 75: 437-443.
23. Kawakami, M., T. Murase, H. Itakura, N. Yamada, N. Ohsawa, and F. Takaku. 1986. Lipid metabolism in endotoxic rats: decrease in hepatic triglyceride lipase activity. Microbiol. Immunol. 30: 849-854.
24. Auerbach, B. J., and J. S. Parks. 1989. Lipoprotein abnormalities associated with lipopolysaccharide-induced lecithin:cholesterol acyltransferase and lipase deficiency. J. Biol. Chem. 264: 10264-10270.
25. Ettinger, W. H., L. D. Miller, J. J. Albers, T. K. Smith, and J. S. Parks. 1990. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J. Lipid Res. 31: 1099-1107.
26. Feingold, K. R., I. Staprans, R. A. Memon, A. H. Moser, J. K. Shigenaga, W. Doerrler, C. A. Dinarello, and C. Grunfeld. 1992. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J. Lipid Res. 33: 1765-1776.
27. Feingold, K. R., I. Hardardottir, R. Memon, E. J. Krul, A. H. Moser, J. M. Taylor, and C. Grunfeld. 1993. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J. Lipid Res. 34: 2147-2158.
28. Nonogaki, K., A. H. Moser, X. M. Pan, I. Staprans, C. Grunfeld, and K. R. Feingold. 1995. Lipoteichoic acid stimulates lipolysis and hepatic triglyceride secretion in rats in vivo. J. Lipid Res. 36: 1987-1995.
29. Feingold, K. R., and C. Grunfeld. 1987. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J. Clin. Invest. 80: 184-190.
30. Argiles, J. M., F. J. Lopez-Soriano, R. D. Evans, and D. H. Williamson. 1989. Interleukin-1 and lipid metabolism in the rat. Biochem. J. 259: 673-678.
31. Feingold, K. R., M. Soued, M. K. Serio, A. H. Moser, C. A. Dinarello, and C. Grunfeld. 1989. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology. 125: 267-274.
32. Feingold, K. R., M. Soued, S. Adi, I. Staprans, R. Neese, J. Shigenaga, W. Doerrler, A. Moser, C. A. Dinarello, and C. Grunfeld. 1991. Effect of interleukin-1 on lipid metabolism in the rat. Similarities to and differences from tumor necrosis factor. Arterioscler. Thromb. 11: 495-500.
33. Memon, R. A., C. Grunfeld, A. H. Moser, and K. R. Feingold. 1993. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology. 132: 2246-2253.
34. Nonogaki, K., G. M. Fuller, N. L. Fuentes, A. H. Moser, I. Staprans, C. Grunfeld, and K. R. Feingold. 1995. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology. 136: 2143-2149.
35. Sherman, M. L., D. R. Spriggs, K. A. Arthur, K. Imamura, E. Frei 3rd, and D. W. Kufe. 1988. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J. Clin. Oncol. 6: 344-350.
36. Malmendier, C. L., J. F. Lontie, J. P. Sculier, and D. Y. Dubois. 1988. Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis. 73: 173-180.
37. Starnes, H. F., Jr., R. S. Warren, M. Jeevanandam, J. L. Gabrilove, W. Larchian, H. F. Oettgen, and M. F. Brennan. 1988. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J. Clin. Invest. 82: 1321-1325.
38. Kurzrock, R., M. F. Rohde, J. R. Quesada, S. H. Gianturco, W. A. Bradley, S. A. Sherwin, and J. U. Gutterman. 1986. Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J. Exp. Med. 164: 1093-1101.
39. Olsen, E. A., G. R. Lichtenstein, and W. E. Wilkinson. 1988. Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-n1 (Wellferon). J. Am. Acad. Dermatol. 19: 286-289.
40. Naeem, M., B. R. Bacon, B. Mistry, R. S. Britton, and A. M. Di Bisceglie. 2001. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am. J. Gastroenterol. 96: 2468-2472.
41. Chajek-Shaul, T., G. Friedman, O. Stein, E. Shiloni, J. Etienne, and Y. Stein. 1989. Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. Biochim. Biophys. Acta. 1001: 316-324.
42. Rosenzweig, I. B., D. A. Wiebe, J. A. Hank, J. J. Albers, J. L. Adolphson, E. Borden, E. S. Shrago, and P. M. Sondel. 1990. Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein. Biotherapy. 2: 193-198.
43. Nonogaki, K., X. M. Pan, A. H. Moser, J. Shigenaga, I. Staprans, N. Sakamoto, C. Grunfeld, and K. R. Feingold. 1996. LIF and CNTF, which share the gp130 transduction system, stimulate hepatic lipid metabolism in rats. Am. J. Physiol. 271: E521-E528.
44. Nonogaki, K., A. H. Moser, J. Shigenaga, K. R. Feingold, and C. Grunfeld. 1996. Beta-nerve growth factor as a mediator of the acute phase response in vivo. Biochem. Biophys. Res. Commun. 219: 956-961.
45. Nonogaki, K., X. M. Pan, A. H. Moser, I. Staprans, K. R. Feingold, and C. Grunfeld. 1995. Keratinocyte growth factor increases fatty acid mobilization and hepatic triglyceride secretion in rats. Endocrinology. 136: 4278-4284.
46. Evans, R. D., V. Ilic, and D. H. Williamson. 1991. Effects of platelet-activating factor on lipid metabolism in rats in vivo. Origin of the hypertriglyceridaemia. Biochem. J. 280: 541-543.
47. Funk, J. L., A. H. Moser, C. Grunfeld, and K. R. Feingold. 1997. Parathyroid hormone-related protein is induced in the adult liver during endotoxemia and stimulates the hepatic acute phase response. Endocrinology. 138: 2665-2673.
48. Grunfeld, C., M. Soued, S. Adi, A. H. Moser, W. Fiers, C. A. Dinarello, and K. R. Feingold. 1991. Interleukin 4 inhibits stimulation of hepatic lipogenesis by tumor necrosis factor, interleukin 1, and interleukin 6 but not by interferon-alpha. Cancer Res. 51: 2803-2807.
49. Feingold, K. R., M. Soued, I. Staprans, L. A. Gavin, M. E. Donahue, B. J. Huang, A. H. Moser, R. Gulli, and C. Grunfeld. 1989. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J. Clin. Invest. 83: 1116-1121.
50. Evans, R. D., and D. H. Williamson. 1991. Comparison of effects of platelet-activating factor and tumour necrosis factor-alpha on lipid metabolism in adrenalectomized rats in vivo. Biochim. Biophys. Acta. 1086: 191-196.
51. Feingold, K. R., M. Soued, M. K. Serio, S. Adi, A. H. Moser, and C. Grunfeld. 1990. The effect of diet on tumor necrosis factor stimulation of hepatic lipogenesis. Metabolism. 39: 623-632.
52. Feingold, K. R., S. Adi, I. Staprans, A. H. Moser, R. Neese, J. A. Verdier, W. Doerrler, and C. Grunfeld. 1990. Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am. J. Physiol. 259: E177-E184.
53. Grunfeld, C., M. Soued, S. Adi, A. H. Moser, C. A. Dinarello, and K. R. Feingold. 1990. Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha. Endocrinology. 127: 46-54.
54. Tripp, R. J., A. Tabares, H. Wang, and S. Lanza-Jacoby. 1993. Altered hepatic production of apolipoproteins B and E in the fasted septic rat: factors in the development of hypertriglyceridemia. J. Surg. Res. 55: 465-472.
55. Feingold, K. R., M. K. Serio, S. Adi, A. H. Moser, and C. Grunfeld. 1989. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology. 124: 2336-2342.
56. Grunfeld, C., J. A. Verdier, R. Neese, A. H. Moser, and K. R. Feingold. 1988. Mechanisms by which tumor necrosis factor stimulates hepatic fatty acid synthesis in vivo. J. Lipid Res. 29: 1327-1335.
57. Kiuchi, S., N. Matsuo, N. Takeyama, and T. Tanaka. 1993. Accelerated hepatic lipid synthesis in fasted septic rats. Eur. Surg. Res. 25: 146-154.
58. Hikawyj-Yevich, I., and J. A. Spitzer. 1977. Endotoxin influence on lipolysis in isolated human and primate adipocytes. J. Surg. Res. 23: 106-113.
59. Spitzer, J. J. 1979. Lipid metabolism in endotoxic shock. Circ. Shock. (Suppl. 1): 69-79.
60. Green, A., S. B. Dobias, D. J. Walters, and A. R. Brasier. 1994. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology. 134: 2581-2588.
61. Kawakami, M., T. Murase, H. Ogawa, S. Ishibashi, N. Mori, F. Takaku, and S. Shibata. 1987. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J. Biochem. (Tokyo). 101: 331-338.
62. Hauner, H., T. Petruschke, M. Russ, K. Rohrig, and J. Eckel. 1995. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia. 38: 764-771.
63. Memon, R. A., K. R. Feingold, A. H. Moser, W. Doerrler, and C. Grunfeld. 1992. In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis. Endocrinology. 131: 1695-1702.
64. Doerrler, W., K. R. Feingold, and C. Grunfeld. 1994. Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms. Cytokine. 6: 478-484.
65. Zhang, H. H., M. Halbleib, F. Ahmad, V. C. Manganiello, and A. S. Greenberg. 2002. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes. 51: 2929-2935.
66. Greenberg, A. S., W. J. Shen, K. Muliro, S. Patel, S. C. Souza, R. A. Roth, and F. B. Kraemer. 2001. Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J. Biol. Chem. 276: 45456-45461.
67. Memon, R. A., K. R. Feingold, A. H. Moser, J. Fuller, and C. Grunfeld. 1998. Regulation of fatty acid transport protein and fatty acid translocase mRNA levels by endotoxin and cytokines. Am. J. Physiol. 274: E210-E217.
68. Memon, R. A., J. Fuller, A. H. Moser, P. J. Smith, K. R. Feingold, and C. Grunfeld. 1998. In vivo regulation of acyl-CoA synthetase mRNA and activity by endotoxin and cytokines. Am. J. Physiol. 275: E64-E72.
69. Beylot, M., M. Guiraud, G. Grau, and P. Bouletreau. 1989. Regulation of ketone body flux in septic patients. Am. J. Physiol. 257: E665-E674.
70. Takeyama, N., Y. Itoh, Y. Kitazawa, and T. Tanaka. 1990. Altered hepatic mitochondrial fatty acid oxidation and ketogenesis in endotoxic rats. Am. J. Physiol. 259: E498-E505.
71. Memon, R. A., N. M. Bass, A. H. Moser, J. Fuller, R. Appel, C. Grunfeld, and K. R. Feingold. 1999. Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim. Biophys. Acta. 1440: 118-126.
72. Barke, R. A., S. Birklid, R. B. Chapin, S. Roy, P. S. Brady, and L. J. Brady. 1996. The effect of surgical treatment following peritoneal sepsis on hepatic gene expression. J. Surg. Res. 60: 101-106.
73. Andrejko, K. M., and C. S. Deutschman. 1997. Altered hepatic gene expression in fecal peritonitis: changes in transcription of gluconeogenic, beta-oxidative, and ureagenic genes. Shock. 7: 164-169.
74. Memon, R. A., K. R. Feingold, A. H. Moser, W. Doerrler, S. Adi, C. A. Dinarello, and C. Grunfeld. 1992. Differential effects of interleukin-1 and tumor necrosis factor on ketogenesis. Am. J. Physiol. 263: E301-E309.
75. Romanosky, A. J., G. J. Bagby, E. L. Bockman, and J. J. Spitzer. 1980. Free fatty acid utilization by skeletal muscle after endotoxin administration. Am. J. Physiol. 239: E391-E395.
76. Romanosky, A. J., G. J. Bagby, E. L. Bockman, and J. J. Spitzer. 1980. Increased muscle glucose uptake and lactate release after endotoxin administration. Am. J. Physiol. 239: E311-E316.
77. Lanza-Jacoby, S., K. Feagans, and A. Tabares. 1989. Fatty acid metabolism in the heart during Escherichia coli sepsis in the rat. Circ. Shock. 29: 361-370.
78. Friedman, G., V. Barak, T. Chajek-Shaul, J. Etienne, A. J. Treves, O. Stein, and Y. Stein. 1991. Recombinant human interleukin-1 suppresses lipoprotein lipase activity, but not expression of lipoprotein lipase mRNA in mesenchymal rat heart cell cultures. Biochim. Biophys. Acta. 1089: 83-87.
79. Enerback, S., H. Semb, J. Tavernier, G. Bjursell, and T. Olivecrona. 1988. Tissue-specific regulation of guinea pig lipoprotein lipase: effects of nutritional state and of tumor necrosis factor on mRNA levels in adipose tissue, heart and liver. Gene. 64: 97-106.
80. Feingold, K. R., M. Marshall, R. Gulli, A. H. Moser, and C. Grunfeld. 1994. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler. Thromb. 14: 1866-1872.
81. Beutler, B., and A. Cerami. 1986. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 320: 584-588.
82. Patton, J. S., H. M. Shepard, H. Wilking, G. Lewis, B. B. Aggarwal, T. E. Eessalu, L. A. Gavin, and C. Grunfeld. 1986. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc. Natl. Acad. Sci. USA. 83: 8313-8317.
83. Grunfeld, C., R. Gulli, A. H. Moser, L. A. Gavin, and K. R. Feingold. 1989. Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J. Lipid Res. 30: 579-585.
84. Feingold, K. R., M. Soued, S. Adi, I. Staprans, J. Shigenaga, W. Doerrler, A. Moser, and C. Grunfeld. 1990. Tumor necrosis factor-increased hepatic very-low-density lipoprotein production and increased serum triglyceride levels in diabetic rats. Diabetes. 39: 1569-1574.
85. Hardardóttir, I., J. Sipe, A. H. Moser, C. J. Fielding, K. R. Feingold, and C. Grünfeld. 1997. LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochim. Biophys. Acta. 1344: 210-220.
86. Lanza-Jacoby, S., S. H. Wong, A. Tabares, D. Baer, and T. Schneider. 1992. Disturbances in the composition of plasma lipoproteins during gram-negative sepsis in the rat. Biochim. Biophys. Acta. 1124: 233-240.
87. Phetteplace, H., M. Maniscalco, and S. Lanza-Jacoby. 1994. The catabolism of apolipoprotein B from very low density lipoprotein and triglyceride-rich lipoprotein remnants in fasted septic rats. Shock. 1: 217-220.
88. Feingold, K. R., A. S. Pollock, A. H. Moser, J. K. Shigenaga, and C. Grunfeld. 1995. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J. Lipid Res. 36: 1474-1482.
89. Memon, R. A., I. Shechter, A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 1997. Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. J. Lipid Res. 38: 1620-1629.
90. Mookerjea, S., T. Coolbear, and M. L. Sarkar. 1983. Rev role of dolichol phosphate in glycoprotein biosynthesis. Can. J. Biochem. Cell Biol. 61: 1032-1040.
91. Sarkar, M., and S. Mookerjea. 1988. Differential effect of inflammation and dexamethasone on dolichol and dolichol phosphate synthesis. Biochem. Cell Biol. 66: 1265-1269.
92. Hardardóttir, I., A. H. Moser, R. Memon, C. Grünfeld, and K. R. Feingold. 1994. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res. 13: 161-166.
93. Spriggs, D. R., M. L. Sherman, H. Michie, K. A. Arthur, K. Imamura, D. Wilmore, E. Frei 3rd, and D. W. Kufe. 1988. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J. Natl. Cancer Inst. 80: 1039-1044.
94. Rosenzweig, I. B., D. A. Wiebe, E. C. Borden, B. Storer, and E. S. Shrago. 1987. Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis. 67: 261-267.
95. Nimer, S. D., R. E. Champlin, and D. W. Golde. 1988. Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. J. Am. Med. Assoc. 260: 3297-3300.
96. Stoudemire, J. B., and M. B. Garnick. 1991. Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels. Blood. 77: 750-755.
97. Ettinger, W. H., L. A. Miller, T. K. Smith, and J. S. Parks. 1992. Effect of interleukin-1 alpha on lipoprotein lipids in cynomolgus monkeys: comparison to tumor necrosis factor. Biochim. Biophys. Acta. 1128: 186-192.
98. Ettinger, W. H., V. K. Varma, M. Sorci-Thomas, J. S. Parks, R. C. Sigmon, T. K. Smith, and R. B. Verdery. 1994. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler. Thromb. 14: 8-13.
99. Schectman, G., S. Kaul, R. A. Mueller, E. C. Borden, and A. H. Kissebah. 1992. The effect of interferon on the metabolism of LDLs. Arterioscler. Thromb. 12: 1053-1062.
100. Xu, N., and A. Nilsson. 1996. Endotoxin inhibits catabolism of low density lipoproteins in vivo: an experimental study in the rat. Scand. J. Clin. Lab. Invest. 56: 53-61.
101. Liao, W., M. Rudling, and B. Angelin. 1999. Endotoxin suppresses mouse hepatic low-density lipoprotein-receptor expression via a pathway independent of the Toll-like receptor 4. Hepatology. 30: 1252-1256.
102. Moorby, C. D., E. Gherardi, L. Dovey, C. Godliman, and D. E. Bowyer. 1992. Transforming growth factor-beta 1 and interleukin-1 beta stimulate LDL receptor activity in Hep G2 cells. Atherosclerosis. 97: 21-28.
103. Liao, W., and C. H. Floren. 1993. Tumor necrosis factor up-regulates expression of low-density lipoprotein receptors on HepG2 cells. Hepatology. 17: 898-907.
104. Bjorkhem, I., and G. Eggertsen. 2001. Genes involved in initial steps of bile acid synthesis. Curr. Opin. Lipidol. 12: 97-103.
105. Russell, D. W. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72: 137-174.
106. Trauner, M., and J. L. Boyer. 2003. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83: 633-671.
107. Yu, L., R. E. Hammer, J. Li-Hawkins, K. Von Bergmann, D. Lutjohann, J. C. Cohen, H. H. Hobbs, K. E. Berge, J. D. Horton, G. A. Graf, W. P. Li, R. D. Gerard, I. Gelissen, and A. White. 2002. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. USA. 99: 16237-16242.
108. Yu, L., J. Li-Hawkins, R. E. Hammer, K. E. Berge, J. D. Horton, J. C. Cohen, H. H. Hobbs, G. A. Graf, W. P. Li, R. D. Gerard, I. Gelissen, and A. White. 2002. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 110: 671-680.
109. Feingold, K. R., D. K. Spady, A. S. Pollock, A. H. Moser, and C. Grunfeld. 1996. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J. Lipid Res. 37: 223-228.
110. Memon, R. A., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2001. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. Potential role of hepatocyte nuclear factor-1. J. Biol. Chem. 276: 30118-30126.
111. Green, R. M., D. Beier, and J. L. Gollan. 1996. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology. 111: 193-198.
112. Moseley, R. H., W. Wang, H. Takeda, K. Lown, L. Shick, M. Ananthanarayanan, and F. J. Suchy. 1996. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am. J. Physiol. 271: G137-G146.
113. Trauner, M., M. Arrese, H. Lee, J. L. Boyer, and S. J. Karpen. 1998. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J. Clin. Invest. 101: 2092-2100.
114. Hartmann, G., A. K. Cheung, and M. Piquette-Miller. 2002. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303: 273-281.
115. Vos, T. A., G. J. Hooiveld, H. Koning, S. Childs, D. K. Meijer, H. Moshage, P. L. Jansen, and M. Muller. 1998. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology. 28: 1637-1644.
116. Tygstrup, N., K. Bangert, P. Ott, and H. C. Bisgaard. 2002. Messenger RNA profiles in liver injury and stress: a comparison of lethal and nonlethal rat models. Biochem. Biophys. Res. Commun. 290: 518-525.
117. Khovidhunkit, W., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2003. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J. Lipid Res. 44: 1728-1736.
118. Scanu, A. M. 2003. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr. Atheroscler. Rep. 5: 106-113.
119. Karabina, S. A., M. C. Elisaf, J. Goudevenos, K. C. Siamopoulos, D. Sideris, and A. D. Tselepis. 1996. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro. Atherosclerosis. 125: 121-134.
120. Maeda, S., A. Abe, M. Seishima, K. Makino, A. Noma, and M. Kawade. 1989. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 78: 145-150.
121. Wallberg-Jonsson, S., A. Uddhammar, G. Dahlen, and S. Rantapaa-Dahlqvist. 1995. Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Scand. J. Clin. Lab. Invest. 55: 309-315.
122. Andreassen, A. K., K. Berg, and H. Torsvik. 1994. Changes in Lp(a) lipoprotein and other plasma proteins during acute myocardial infarction. Clin. Genet. 46: 410-416.
123. Mooser, V., M. M. Berger, L. Tappy, C. Cayeux, S. M. Marcovina, R. Darioli, P. Nicod, and R. Chiolero. 2000. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler. Thromb. Vasc. Biol. 20: 1137-1142.
124. Cabana, V. G., J. N. Siegel, and S. M. Sabesin. 1989. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 30: 39-49.
125. Clifton, P. M., A. M. Mackinnon, and P. J. Barter. 1985. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J. Lipid Res. 26: 1389-1398.
126. Cabana, V. G., J. R. Lukens, K. S. Rice, T. J. Hawkins, and G. S. Getz. 1996. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J. Lipid Res. 37: 2662-2674.
127. Pruzanski, W., E. Stefanski, F. C. de Beer, M. C. de Beer, A. Ravandi, and A. Kuksis. 2000. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res. 41: 1035-1047.
128. Memon, R. A., W. M. Holleran, A. H. Moser, T. Seki, Y. Uchida, J. Fuller, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 1998. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler. Thromb. Vasc. Biol. 18: 1257-1265.
129. Hoffman, J. S., and E. P. Benditt. 1982. Changes in high density lipoprotein content following endotoxin administration in the mouse. Formation of serum amyloid protein-rich subfractions. J. Biol. Chem. 257: 10510-10517.
130. Lindhorst, E., D. Young, W. Bagshaw, M. Hyland, and R. Kisilevsky. 1997. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim. Biophys. Acta. 1339: 143-154.
131. Sakaguchi, S. 1982. Metabolic disorders of serum lipoproteins in endotoxin-poisoned mice: the role of high density lipoprotein (HDL) and triglyceride-rich lipoproteins. Microbiol. Immunol. 26: 1017-1034.
132. Barlage, S., D. Frohlich, A. Bottcher, M. Jauhiainen, H. P. Muller, F. Noetzel, G. Rothe, C. Schutt, R. P. Linke, K. J. Lackner, C. Ehnholm, and G. Schmitz. 2001. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J. Lipid Res. 42: 281-290.
133. Hardardóttir, I., S. T. Kunitake, A. H. Moser, W. T. Doerrler, J. H. Rapp, C. Grünfeld, and K. R. Feingold. 1994. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J. Clin. Invest. 94: 1304-1309.
134. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.
135. Van Lenten, B. J., A. C. Wagner, D. P. Nayak, S. Hama, M. Navab, and A. M. Fogelman. 2001. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 103: 2283-2288.
136. Ly, H., O. L. Francone, C. J. Fielding, J. K. Shigenaga, A. H. Moser, C. Grunfeld, and K. R. Feingold. 1995. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J. Lipid Res. 36: 1254-1263.
137. Masucci-Magoulas, L., P. Moulin, X. C. Jiang, H. Richardson, A. Walsh, J. L. Breslow, and A. Tall. 1995. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J. Clin. Invest. 95: 1587-1594.
138. Hardardóttir, I., A. H. Moser, J. Fuller, C. Fielding, K. Feingold, and C. Grünfeld. 1996. Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in Syrian hamsters. J. Clin. Invest. 97: 2585-2592.
139. Feingold, K. R., R. A. Memon, A. H. Moser, J. K. Shigenaga, and C. Grunfeld. 1999. Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. Atherosclerosis. 142: 379-387.
140. Feingold, K. R., R. A. Memon, A. H. Moser, and C. Grunfeld. 1998. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 139: 307-315.
141. Memon, R. A., J. Fuller, A. H. Moser, K. R. Feingold, and C. Grunfeld. 1999. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am. J. Physiol. 277: R94-R103.
142. Jiang, X. C., and C. Bruce. 1995. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J. Biol. Chem. 270: 17133-17138.
143. Hudgins, L. C., T. S. Parker, D. M. Levine, B. R. Gordon, S. D. Saal, X. C. Jiang, C. E. Seidman, J. D. Tremaroli, J. Lai, and A. L. Rubin. 2003. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J. Lipid Res. 44: 1489-1498.
144. Pruzanski, W., P. Vadas, and J. Browning. 1993. Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J. Lipid Mediat. 8: 161-167.
145. Cabana, V. G., C. A. Reardon, B. Wei, J. R. Lukens, and G. S. Getz. 1999. SAA-only HDL formed during the acute phase response in apoA-I+/+ and apoA-I-/- mice. J. Lipid Res. 40: 1090-1103.
146. Husebekk, A., B. Skogen, and G. Husby. 1988. High-density lipoprotein has different binding capacity for different apoproteins. The amyloidogenic apoproteins are easier to displace from high-density lipoprotein. Scand. J. Immunol. 28: 653-658.
147. Coetzee, G. A., A. F. Strachan, D. R. van der Westhuyzen, H. C. Hoppe, M. S. Jeenah, and F. C. de Beer. 1986. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261: 9644-9651.
148. Hoffman, J. S., and E. P. Benditt. 1983. Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J. Clin. Invest. 71: 926-934.
149. Hosoai, H., N. R. Webb, J. M. Glick, U. J. Tietge, M. S. Purdom, F. C. de Beer, and D. J. Rader. 1999. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J. Lipid Res. 40: 648-653.
150. de Beer, F. C., M. C. de Beer, D. R. van der Westhuyzen, L. W. Castellani, A. J. Lusis, M. E. Swanson, and D. S. Grass. 1997. Secretory non-pancreatic phospholipase A2: influence on lipoprotein metabolism. J. Lipid Res. 38: 2232-2239.
151. Tietge, U. J., C. Maugeais, W. Cain, D. Grass, J. M. Glick, F. C. de Beer, and D. J. Rader. 2000. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J. Biol. Chem. 275: 10077-10084.
152. Tietge, U. J., C. Maugeais, S. Lund-Katz, D. Grass, F. C. DeBeer, and D. J. Rader. 2002. Human secretory phospholipase A(2) mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler. Thromb. Vasc. Biol. 22: 1213-1218.
153. Jaye, M., K. J. Lynch, J. Krawiec, D. Marchadier, C. Maugeais, K. Doan, V. South, D. Amin, M. Perrone, and D. J. Rader. 1999. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21: 424-428.
154. Ma, K., M. Cilingiroglu, J. D. Otvos, C. M. Ballantyne, A. J. Marian, and L. Chan. 2003. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc. Natl. Acad. Sci. USA. 100: 2748-2753.
155. Ishida, T., S. Choi, R. K. Kundu, K. Hirata, E. M. Rubin, A. D. Cooper, and T. Quertermous. 2003. Endothelial lipase is a major determinant of HDL level. J. Clin. Invest. 111: 347-355.
156. Jin, W., J. S. Millar, U. Broedl, J. M. Glick, and D. J. Rader. 2003. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J. Clin. Invest. 111: 357-362.
157. Jin, W., G. S. Sun, D. Marchadier, E. Octtaviani, J. M. Glick, and D. J. Rader. 2003. Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. Circ. Res. 92: 644-650.
158. Kuivenhoven, J. A., H. Pritchard, J. Hill, J. Frohlich, G. Assmann, and J. Kastelein. 1997. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 38: 191-205.
159. Lamarche, B., K. D. Uffelman, A. Carpentier, J. S. Cohn, G. Steiner, P. H. Barrett, and G. F. Lewis. 1999. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 103: 1191-1199.
160. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36: 211-228.
161. von Eckardstein, A., J. R. Nofer, and G. Assmann. 2001. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21: 13-27.
162. Baranova, I., T. Vishnyakova, A. Bocharov, Z. Chen, A. T. Remaley, J. Stonik, T. L. Eggerman, and A. P. Patterson. 2002. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect. Immun. 70: 2995-3003.
163. Khovidhunkit, W., J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2001. Cholesterol efflux by acute-phase high density lipoprotein. Role of lecithin:cholesterol acyltransferase. J. Lipid Res. 42: 967-975.
164. Khovidhunkit, W., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2001. Regulation of scavenger receptor class B type I in hamster liver and Hep3B cells by endotoxin and cytokines. J. Lipid Res. 42: 1636-1644.
165. Memon, R. A., W. M. Holleran, Y. Uchida, A. H. Moser, S. Ichikawa, Y. Hirabayashi, C. Grunfeld, and K. R. Feingold. 1999. Regulation of glycosphingolipid metabolism in liver during the acute phase response. J. Biol. Chem. 274: 19707-19713.
166. Memon, R. A., W. M. Holleran, Y. Uchida, A. H. Moser, C. Grunfeld, and K. R. Feingold. 2001. Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin. J. Lipid Res. 42: 452-459.
167. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki, and M. Taniguchi. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 278: 1626-1629.
168. Wong, M. L., B. Xie, N. Beatini, P. Phu, S. Marathe, A. Johns, P. W. Gold, E. Hirsch, K. J. Williams, J. Licinio, and I. Tabas. 2000. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc. Natl. Acad. Sci. USA. 97: 8681-8686.
169. Delogu, G., G. Famularo, E Amati, L. Signore, A. Antonucci, V. Trinchieri, L. Di Marzio, and M. G. Cifone. 1999. Ceramide concentrations in septic patients: a possible marker of multiple organ dysfunction syndrome. Crit. Care Med. 27: 2413-2417.
170. Drobnik, W., G. Liebisch, F. X. Audebert, D. Frohlich, T. Gluck, P. Vogel, G. Rothe, and G. Schmitz. 2003. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J. Lipid Res. 44: 754-761.
171. Nikolova-Karakashian, M., E. T. Morgan, C. Alexander, D. C. Liotta, and A. H. Merrill, Jr. 1997. Bimodal regulation of ceramidase by interleukin-1beta. Implications for the regulation of cytochrome p450 2C11. J. Biol. Chem. 272: 1718-18724.
172. Xia, P., J. R. Gamble, K. A. Rye, L. Wang, C. S. Hii, P. Cockerill, Y. Khew-Goodall, A. G. Bert, P. J. Barter, and M. A. Vadas. 1998. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl. Acad. Sci. USA. 95: 14196-14201.
173. Baumann, H., K. R. Prowse, S. Marinkovic, K. A. Won, and G. P. Jahreis. 1989. Stimulation of hepatic acute phase response by cytokines and glucocorticoids. Ann. N. Y. Acad. Sci. 557: 280-295.
174. Kishimoto, T., T. Taga, and S. Akira. 1994. Cytokine signal transduction. Cell. 76: 253-262.
175. Mangelsdorf, D. J., and R. M. Evans. 1995. The RXR heterodimers and orphan receptors. Cell. 83: 841-850.
176. Blumberg, B., and R. M. Evans. 1998. Orphan nuclear receptors - new ligands and new possibilities. Genes Dev. 12: 3149-3155.
177. Kliewer, S. A., J. M. Lehmann, and T. M. Willson. 1999. Orphan nuclear receptors: shifting endocrinology into reverse. Science. 284: 757-760.
178. Chawla, A., J. J. Repa, R. M. Evans, and D. J. Mangelsdorf. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science. 294: 1866-1870.
179. Lee, C. H., P. Olson, and R. M. Evans. 2003. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 144: 2201-2207.
180. Peet, D. J., B. A. Janowski, and D. J. Mangelsdorf. 1998. The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8: 571-575.
181. Edwards, P. A., H. R. Kast, and A. M. Anisfeld. 2002. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43: 2-12.
182. Francis, G. A., E. Fayard, F. Picard, and J. Auwerx. 2003. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65: 261-311.
183. Beigneux, A. P., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2000. The acute phase response is associated with retinoid X receptor repression in rodent liver. J. Biol. Chem. 275: 16390-16399.
184. Kim, M. S., J. Shigenaga, A. Moser, K. Feingold, and C. Grunfeld. 2003. Repression of farnesoid X receptor during the acute phase response. J. Biol. Chem. 278: 8988-8995.
185. Beigneux, A. P., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2002. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem. Biophys. Res. Commun. 293: 145-149.
186. Hill, M. R., M. D. Young, C. M. McCurdy, and J. M. Gimble. 1997. Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. Endocrinology. 138: 3073-3076.
187. Zhang, B., J. Berger, E. Hu, D. Szalkowski, S. White-Carrington, B. M. Spiegelman, and D. E. Moller. 1996. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol. Endocrinol. 10: 1457-1466.
188. Xing, H., J. P. Northrop, J. R. Grove, K. E. Kilpatrick, J. L. Su, and G. M. Ringold. 1997. TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Endocrinology. 138: 2776-2783.
189. Perrey, S., S. Ishibashi, N. Yahagi, J. Osuga, R. Tozawa, H. Yagu, K. Ohashi, T. Gotoda, K. Harada, Z. Chen, Y. Iizuka, F. Shionoiri, and N. Yamada. 2001. Thiazolidinedione- and tumor necrosis factor alpha-induced downregulation of peroxisome proliferator-activated receptor gamma mRNA in differentiated 3T3-L1 adipocytes. Metabolism. 50: 36-40.
190. Waite, K. J., Z. E. Floyd, P. Arbour-Reily, and J. M. Stephens. 2001. Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. J. Biol. Chem. 276: 7062-7068.
191. Meng, L., J. Zhou, H. Sasano, T. Suzuki, K. M. Zeitoun, and S. E. Bulun. 2001. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res. 61: 2250-2255.
192. Feingold, K., M. S. Kim, J. Shigenaga, A. Moser, and C. Grunfeld. 2004. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am. J. Physiol. Endocrinol. Metab. 286: E201-E207.
193. Fajas, L., M. B. Debril, and J. Auwerx. 2001. Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J. Mol. Endocrinol. 27: 1-9.
194. Willson, T. M., M. H. Lambert, and S. A. Kliewer. 2001. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70: 341-367.
195. Fruchart, J. C., P. Duriez, and B. Staels. 1999. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10: 245-257.
196. Wang, Y. X., C. H. Lee, S. Tiep, R. T. Yu, J. Ham, H. Kang, and R. M. Evans. 2003. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 113: 159-170.
197. Lehman, J. J., and D. P. Kelly. 2002. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail. Rev. 7: 175-185.
198. Schoonjans, K., B. Staels, and J. Auwerx. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925.
199. Bagby, G. J., and J. A. Spitzer. 1980. Lipoprotein lipase activity in rat heart and adipose tissue during endotoxic shock. Am. J. Physiol. 238: H325-H330.
200. Bagby, G. J., and J. A. Spitzer. 1981. Decreased myocardial extracellular and muscle lipoprotein lipase activities in endotoxin-treated rats. Proc. Soc. Exp. Biol. Med. 168: 395-398.
201. Sinal, C. J., M. Tohkin, M. Miyata, J. M. Ward, G. Lambert, and F. J. Gonzalez. 2000. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 102: 731-744.
202. Kast, H. R., C. M. Nguyen, C. J. Sinal, S. A. Jones, B. A. Laffitte, K. Reue, F. J. Gonzalez, T. M. Willson, and P. A. Edwards. 2001. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15: 1720-1728.
203. Mak, P. A., H. R. Kast-Woelbern, A. M. Anisfeld, and P. A. Edwards. 2002. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43: 2037-2041.
204. Berg, D. T., D. S. Calnek, and B. W. Grinnell. 1995. The human apolipoprotein E gene is negatively regulated in human liver HepG2 cells by the transcription factor BEF-1. J. Biol. Chem. 270: 15447-15450.
205. Berg, D. T., D. S. Calnek, and B. W. Grinnell. 1996. Trans-repressor BEF-1 phosphorylation. A potential control mechanism for human ApoE gene regulation. J. Biol. Chem. 271: 4589-4592.
206. Oram, J. F., and R. M. Lawn. 2001. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 42: 1173-1179.
207. Venkateswaran, A., B. A. Laffitte, S. B. Joseph, P. A. Mak, D. C. Wilpitz, P. A. Edwards, and P. Tontonoz. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA. 97: 12097-12102.
208. Costet, P., Y. Luo, N. Wang, and A. R. Tall. 2000. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275: 28240-28245.
209. Castrillo, A., S. B. Joseph, S. A. Vaidya, M. Haberland, A. M. Fogelman, G. Cheng, and P. Tontonoz. 2003. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell. 12: 805-816.
210. Tall, A. R., X. Jiang, Y. Luo, and D. Silver. 2000. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20: 1185-1188.
211. Luo, Y., and A. R. Tall. 2000. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105: 513-520.
212. Urizar, N. L., D. H. Dowhan, and D. D. Moore. 2000. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem. 275: 39313-39317.
213. Krieger, M. 2001. Scavenger receptor class B Type I is a multiligand HDL receptor that influences diverse physiologic systems. J. Clin. Invest. 108: 793-797.
214. Malerod, L., M. Sporstol, L. K. Juvet, A. Mousavi, T. Gjoen, and T. Berg. 2003. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha. Biochem. Biophys. Res. Commun. 305: 557-565.
215. Lambert, G., M. J. Amar, G. Guo, H. B. Brewer, Jr., F. J. Gonzalez, and C. J. Sinal. 2003. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278: 2563-2570.
216. Lehmann, J. M., S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, B. B. Oliver, J. L. Su, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, and T. M. Willson. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272: 3137-3140.
217. Peet, D.J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer, and D.J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 93: 693-704.
218. Makishima, M., A. Y. Okamoto, J. J. Repa, H. Tu, R. M. Learned, A. Luk, M. V. Hull, K. D. Lustig, D. J. Mangelsdorf, and B. Shan. 1999. Identification of a nuclear receptor for bile acids. Science. 284: 1362-1365.
219. Chen, J. Y., B. Levy-Wilson, S. Goodart, and A. D. Cooper. 2002. Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed a high fat diet. J. Biol. Chem. 277: 42588-42595.
220. Lu, T. T., M. Makishima, J. J. Repa, K. Schoonjans, T. A. Kerr, J. Auwerx, and D. J. Mangelsdorf. 2000. Molecular basis for feed-back regulation of bile acid synthesis by nuclear receptors. Mol. Cell. 6: 507-515.
221. Gupta, S., W. M. Pandak, and P. B. Hylemon. 2002. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem. Biophys. Res. Commun. 293: 338-343.
222. Chiang, J. Y. 2002. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23: 443-463.
223. Wang, B., S. R. Cai, C. Gao, F. M. Sladek, and K. P. Ponder. 2001. Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver. Hepatology. 34: 979-989.
224. Beigneux, A. P., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2003. Sick euthyroid syndrome is associated with decreased TR expression and DNA binding in mouse liver. Am. J. Physiol. Endocrinol. Metab. 284: E228-E236.
225. del Castillo-Olivares, A., and G. Gil. 2000. Alpha 1-fetoprotein transcription factor is required for the expression of sterol 12alpha-hydroxylase, the specific enzyme for cholic acid synthesis. Potential role in the bile acid-mediated regulation of gene transcription. J. Biol. Chem. 275: 17793-17799.
226. Zhang, M., and J. Y. Chiang. 2001. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. J. Biol. Chem. 276: 41690-41699.
227. Burke, P. A., M. Drotar, M. Luo, M. Yaffe, and R. A. Forse. 1994. Rapid modulation of liver-specific transcription factors after injury. Surgery. 116: 285-292.
228. Garuti, R., M. A. Croce, L. Piccinini, R. Tiozzo, S. Bertolini, and S. Calandra. 2002. Functional analysis of the promoter of human sterol 27-hydroxylase gene in HepG2 cells. Gene. 283: 133-143.
229. Roe, A. L., S. M. Poloyac, G. Howard, S. I. Shedlofsky, and R. A. Blouin. 2001. The effect of endotoxin on hepatocyte nuclear factor 1 nuclear protein binding: potential implications on CYP2E1 expression in the rat. J. Pharm. Pharmacol. 53: 1365-1371.
230. Ananthanarayanan, M., N. Balasubramanian, M. Makishima, D.J. Mangelsdorf, and F. J. Suchy. 2001. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276: 28857-28865.
231. Kast, H. R., B. Goodwin, P. T. Tarr, S. A. Jones, A. M. Anisfeld, C. M. Stoltz, P. Tontonoz, S. Kliewer, T. M. Willson, and P. A. Edwards. 2002. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277: 2908-2915.
232. Repa, J. J., K. E. Berge, C. Pomajzl, J. A. Richardson, H. Hobbs, and D. J. Mangelsdorf. 2002. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277: 18793-18800.
233. Kok, T., V. W. Bloks, H. Wolters, R. Havinga, P. L. Jansen, B. Staels, and E Kuipers. 2003. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369: 539-547.
234. Libby, P., D. Egan, and S. Skarlatos. 1997. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 96: 4095-4103.
235. Epstein, S. E., Y. F. Zhou, and J. Zhu. 1999. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. 100: e20-e28.
236. Becker, A. E., O. J. de Boer, and A. C. van Der Wal. 2001. The role of inflammation and infection in coronary artery disease. Annu. Rev. Med. 52: 289-297.
237. Leinonen, M., and P. Saikku. 2002. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect. Dis. 2: 11-17.
238. Saikku, P., M. Leinonen, L. Tenkanen, E. Linnanmaki, M. R. Ekman, V. Manninen, M. Manttari, M. H. Frick, and J. K. Huttunen. 1992. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med. 116: 273-278.
239. Melnick, J. L., E. Adam, and M. E. Debakey. 1993. Cytomegalovirus and atherosclerosis. Eur. Heart J. 14 (Suppl. K): 30-38.
240. Mendall, M. A., P. M. Goggin, N. Molineaux, J. Levy, T. Toosy, D. Strachan, A. J. Camm, and T. C. Northfield. 1994. Relation of Helicobacter pylori infection and coronary heart disease. Br. Heart J. 71: 437-439.
241. DeStefano, F., R. F. Anda, H. S. Kahn, D. F. Williamson, and C. M. Russell. 1993. Dental disease and risk of coronary heart disease and mortality. BMJ. 306: 688-691.
242. Jousilahti, P., E. Vartiainen, J. Tuomilehto, and P. Puska. 1996. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 348: 567-572.
243. Kiechl, S., G. Egger, M. Mayr, C. J. Wiedermann, E. Bonora, F. Oberhollenzer, M. Muggeo, Q. Xu, G. Wick, W. Poewe, and J. Willeit. 2001. Chronic interactions and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 103: 1064-1070.
244. Monson, R. R., and A. P. Hall. 1976. Mortality among arthritics. J. Chronic Dis. 29: 459-467.
245. McDonald, C. J., and P. Calabresi. 1978. Psoriasis and occlusive vascular disease. Br. J. Dermatol. 99: 469-475.
246. Asanuma, Y., A. Oeser, A. K. Shintani, E. Turner, N. Olsen, S. Fazio, M. F. Linton, P. Raggi, and C. M. Stein. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2407-2415.
247. Roman, M. J., B. A. Shanker, A. Davis, M. D. Lockshin, L. Sammaritano, R. Simantov, M. K. Crow, J. E. Schwartz, S. A. Paget, R. B. Devereux, and J. E. Salmon. 2003. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2399-2406.
248. Havel, R. J. 2000. Remnant lipoproteins as therapeutic targets. Curr. Opin. Lipidol. 11: 615-620.
249. Malloy, M. J., and J. P. Kane. 2001. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv. Intern. Med. 47: 111-136.
250. Ginsberg, H. N. 2002. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 106: 2137-2142.
251. Gianturco, S. H., S. G. Eskin, L. T. Navarro, C. J. Lahart, L. C. Smith, and A. M. Gotto, Jr. 1980. Abnormal effects of hypertriacylglycerolemic very low-density lipoproteins on 3-hydroxy-3-methylglutaryl-CoA reductase activity and viability of cultured bovine aortic endothelial cells. Biochim. Biophys. Acta. 618: 143-152.
252. Gianturco, S. H., M. P. Ramprasad, R. Song, R. Li, M. L. Brown, and W. A. Bradley. 1998. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler. Thromb. Vasc. Biol. 18: 968-976.
253. Redgrave, T. G., V. Rakic, B. C. Mortimer, and J. C. Mamo. 1992. Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins from plasma. Studies with lipid emulsions in rats. Biochim. Biophys. Acta. 1126: 65-72.
254. Feingold, K. R., R. M. Krauss, M. Pang, W. Doerrler, P. Jensen, and C. Grunfeld. 1993. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab. 76: 1423-1427.
255. Nigon, F., P. Lesnik, M. Rouis, and M.J. Chapman. 1991. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J. Lipid Res. 32: 1741-1753.
256. Hurt-Camejo, E., G. Camejo, B. Rosengren, F. Lopez, O. Wiklund, and G. Bondjers. 1990. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J. Lipid Res. 31: 1387-1398.
257. Chait, A., R. L. Brazg, D. L. Tribble, and R. M. Krauss. 1993. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 94: 350-356.
258. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
259. Memon, R. A., I. Staprans, M. Noor, W. M. Holleran, Y. Uchida, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2000. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 20: 1536-1542.
260. Liuba, P., J. Persson, J. Luoma, S. Yla-Herttuala, and E. Pesonen. 2003. Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. Eur. Heart J. 24: 515-521.
261. Pepys, M. B., and G. M. Hirschfield. 2003. C-reactive protein: a critical update. J. Clin. Invest. 111: 1805-1812.
262. de Beer, F. C., A. K. Soutar, M. L. Baltz, I. M. Trayner, A. Feinstein, and M. B. Pepys. 1982. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J. Exp. Med. 156: 230-242.
263. Libby, P., and P. M. Ridker. 1999. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 100: 1148-1150.
264. Chang, M. K., C. J. Binder, M. Torzewski, and J. L. Witztum. 2002. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. USA. 99: 13043-13048.
265. Hakala, J. K., K. Oorni, M. O. Pentikainen, E. Hurt-Camejo, and P. T. Kovanen. 2001. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thromb. Vasc. Biol. 21: 1053-1058.
266. Ivandic, B., L. W. Castellani, X. P. Wang, J. H. Qiao, M. Mehrabian, M. Navab, A. M. Fogelman, D. S. Grass, M. E. Swanson, M. C. de Beer, F. de Beer, and A. J. Lusis. 1999. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 19: 1284-1290.
267. Stafforini, D. M., T. M. McIntyre, M. E. Carter, and S. M. Prescott. 1987. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262: 4215-4222.
268. Steinbrecher, U. P., and P. H. Pritchard. 1989. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J. Lipid Res. 30: 305-315.
269. Quinn, M. T., S. Parthasarathy, and D. Steinberg. 1988. Lysophos-phatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. USA. 85: 2805-2809.
270. Kugiyama, K., S. A. Kerns, J. D. Morrisett, R. Roberts, and P. D. Henry. 1990. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344: 160-162.
271. Khovidhunkit, W., R. A. Memon, J. K. Shigenaga, M. Pang, M. Schambelan, K. Mulligan, K. R. Feingold, and C. Grunfeld. 1999. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism. 48: 1524-1531.
272. Packard, C. J., D. S. O'Reilly, M. J. Caslake, A. D. McMahon, I. Ford, J. Cooney, C. H. Macphee, K. E. Suckling, M. Krishna, F. E. Wilkinson, A. Rumley, and G. D. Lowe. 2000. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343: 1148-1155.
273. Schissel, S. L., J. Tweedie-Hardman, J. H. Rapp, G. Graham, K.J. Williams, and I. Tabas. 1996. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 98: 1455-1464.
274. Mukhin, D. N., F. F. Chao, and H. S. Kruth. 1995. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15: 1607-1615.
275. Jeong, T., S. L. Schissel, I. Tabas, H.J. Pownall, A. R. Tall, and X. Jiang. 1998. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production ducfion and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J. Clin. Invest. 101: 905-912.
276. Jiang, X. C., F. Paultre, T. A. Pearson, R. G. Reed, C. K. Francis, M. Lin, L. Berglund, and A. R. Tall. 2000. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 20: 2614-2618.
277. Xu, X. X., and I. Tabas. 1991. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J. Biol. Chem. 266: 24849-24858.
278. Artl, A., G. Marsche, S. Lestavel, W. Sattler, and E. Malle. 2000. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol. 20: 763-772.
279. Pussinen, P. J., M. Jauhiainen, T. Vilkuna-Rautiainen, J. Sundvall, M. Vesanen, K. Mattila, T. Palosuo, G. Alfthan, and S. Asikainen. 2004. Periodontitis decreases the antiatherogenic potency of high density lipoprotein. J. Lipid Res. 45: 139-147.
280. Artl, A., G. Marsche, P. Pussinen, G. Knipping, W. Sattler, and E. Malle. 2002. Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int. J. Biochem. Cell Biol. 34: 370-381.
281. Kunitake, S. T., M. R. Jarvis, R. L. Hamilton, and J. P. Kane. 1992. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc. Natl. Acad. Sci. USA. 89: 6993-6997.
282. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, and A. J. Lusis. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
283. Goldstein, I. M., H. B. Kaplan, H. S. Edelson, and G. Weissmann. 1982. Ceruloplasmin: an acute phase reactant that scavenges oxygen-derived free radicals. Ann. N. Y. Acad. Sci. 389: 368-379.
284. Ehrenwald, E., G. M. Chisolm, and P. L. Fox. 1994. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J. Clin. Invest. 93: 1493-1501.
285. Lamb, D. J., and D. S. Leake. 1994. Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett. 338: 122-126.
286. Buttenschoen, K., D. C. Buttenschoen, D. Berger, C. Vasilescu, S. Schafheutle, B. Goeltenboth, M. Seidelmann, and H. G. Beger. 2001. Endotoxemia and acute-phase proteins in major abdominal surgery. Am. J. Surg. 181: 36-43.
287. Oiknine, J., and M. Aviram. 1992. Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler. Thromb. 12: 745-753.
288. Funk, J. L., K. R. Feingold, A. H. Moser, and C. Grunfeld. 1993. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis. 98: 67-82.
289. Ruan, X. Z., Z. Varghese, S. H. Powis, and J. F. Moorhead. 2001. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int. 60: 1716-1725.
290. Kalayoglu, M. V., and G. I. Byrne. 1998. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect. Immun. 66: 5067-5072.
291. Rall, D. P., J. R. Gaskins, and M. G. Kelly. 1957. Reduction of febrile response to bacterial polysaccharide following incubation with serum. Am. J. Physiol. 188: 559-562.
292. Skarnes, R. C., F. S. Rosen, M. J. Shear, and M. Landy. 1958. Inactivation of endotoxin by a humoral component. II. Interaction of endotoxin with serum and plasma. J. Exp. Med. 108: 685-699.
293. Ulevitch, R. J., A. R. Johnston, and D. B. Weinstein. 1979. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J. Clin. Invest. 64: 1516-1524.
294. Munford, R. S., C. L. Hall, J. M. Lipton, and J. M. Dietschy. 1982. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J. Clin. Invest. 70: 877-888.
295. Van Lenten, B. J., A. M. Fogelman, M. E. Haberland, and P. A. Edwards. 1986. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. USA. 83: 2704-2708.
296. Harris, H. W., C. Grunfeld, K. R. Feingold, and J. H. Rapp. 1990. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J. Clin. Invest. 86: 696-702.
297. Eichbaum, E. B., H. W. Harris, J. P. Kane, and J. H. Rapp. 1991. Chylomicrons can inhibit endotoxin activity in vitro. J. Surg. Res. 51: 413-416.
298. Harris, H. W., E. B. Eichbaum, J. P. Kane, and J. H. Rapp. 1991. Detection of endotoxin in triglyceride-rich lipoproteins in vitro. J. Lab. Clin. Med. 118: 186-193.
299. Emancipator, K., G. Csako, and R. J. Elin. 1992. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipo-proteins. Infect. Immun. 60: 596-601.
300. Netea, M. G., N. de Bont, P. N. Demacker, B. J. Kullberg, L. E. Jacobs, T. J. Verver-Jansen, A. F. Stalenhoef, and J. W. Van der Meer. 1998. Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells. Infect. Immun. 66: 2365-2367.
301. Parker, T. S., D. M. Levine, J. C. Chang, J. Laxer, C. C. Coffin, and A. L. Rubin. 1995. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63: 253-258.
302. Grunfeld, C., M. Marshall, J. K. Shigenaga, A. H. Moser, P. Tobias, and K. R. Feingold. 1999. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J. Lipid Res. 40: 245-252.
303. Bhakdi, S., J. Tranum-Jensen, G. Utermann, and R. Fussle. 1983. Binding and partial inactivation of Staphylococcus aureus alphatoxin by human plasma low density lipoprotein. J. Biol. Chem. 258: 5899-5904.
304. Levels, J. H., P. R. Abraham, A. van den Ende, and S. J. van Deventer. 2001. Distribution and kinetics of lipoprotein-bound endotoxin. Infect. Immun. 69: 2821-2828.
305. Levels, J. H., P. R. Abraham, E. P. van Barreveld, J. C. Meijers, and S. J. van Deventer. 2003. Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect. Immun. 71: 3280-3284.
306. Kitchens, R. L., and P. A. Thompson. 2003. Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins. J. Endotoxin Res. 9: 113-118.
307. Kitchens, R. L., P. A. Thompson, R. S. Munford, and G. E. O'Keefe. 2003. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J. Lipid Res. 44: 2339-2348.
308. Eggesbo, J. B., T. Lyberg, T. Aspelin, I. Hjermann, and P. Kierulf. 1996. Different binding of 1251-LPS to plasma proteins from persons with high or low HDL. Scand. J. Clin. Lab. Invest. 56: 533-543.
309. Harris, H. W., C. Grunfeld, K. R. Feingold, T. E. Read, J. P. Kane, A. L. Jones, E. B. Eichbaum, G. F. Bland, and J. H. Rapp. 1993. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J. Clin. Invest. 91: 1028-1034.
310. Hubsch, A. P., F. S. Powell, P. G. Lerch, and J. E. Doran. 1993. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ. Shock. 40: 14-23.
311. Hubsch, A. P., A. T. Casas, and J. E. Doran. 1995. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J. Lab. Clin. Med. 126: 548-558.
312. Casas, A. T., A. P. Hubsch, and J. E. Doran. 1996. Effects of reconstituted high-density lipoprotein in persistent gram-negative bacteremia. Am. Surg. 62: 350-355.
313. Read, T. E., C. Grunfeld, Z. Kumwenda, M. C. Calhoun, J. P. Kane, K. R. Feingold, and J. H. Rapp. 1995. Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats. Surgery. 117: 62-67.
314. Read, T. E., C. Grunfeld, Z. L. Kumwenda, M. C. Calhoun, J. P. Kane, K. R. Feingold, and J. H. Rapp. 1995. Triglyceride-rich lipoproteins prevent septic death in rats. J. Exp. Med. 182: 267-272.
315. Feingold, K. R., J. L. Funk, A. H. Moser, J. K. Shigenaga, J. H. Rapp, and C. Grunfeld. 1995. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect. Immun. 63: 2041-2046.
316. Levine, D. M., T. S. Parker, T. M. Donnelly, A. Walsh, and A. L. Rubin. 1993. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA. 90: 12040-12044.
317. Netea, M. G., P. N. Demacker, B. J. Kullberg, O. C. Boerman, I. Verschueren, A. F. Stalenhoef, and J. W. van der Meer. 1996. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J. Clin. Invest. 97: 1366-1372.
318. Netea, M. G., P. N. Demacker, B. J. Kullberg, L. E. Jacobs, T. J. Verver-Jansen, O. C. Boerman, A. F. Stalenhoef, and J. W. Van der Meer. 1998. Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. Cytokine. 10: 766-772.
319. Pajkrt, D., J. E. Doran, F. Koster, P. G. Lerch, B. Arnet, T. van der Poll, J. W. ten Cate, and S. J. van Deventer. 1996. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184: 1601-1608.
320. Harris, H. W., J. A. Johnson, and S. J. Wigmore. 2002. Endogenous lipoproteins impact the response to endotoxin in humans. Crit. Care Med. 30: 23-31.
321. van der Poll, T., C. C. Braxton, S. M. Coyle, M. A. Boermeester, J. C. Wang, P. M.Jansen, W. J. Montegut, S. E. Calvano, C. E. Hack, and S. F. Lowry. 1995. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect. Immun. 63: 3396-3400.
322. Read, T. E., H. W. Harris, C. Grunfeld, K. R. Feingold, M. C. Calhoun, J. P. Kane, and J. H. Rapp. 1993. Chylomicrons enhance endotoxin excretion in bile. Infect. Immun. 61: 3496-3502.
323. Kumwenda, Z. L., C. B. Wong, J. A. Johnson, J. E. Gosnell, W.J. Welch, and H. W. Harris. 2002. Chylomicron-bound endotoxin selectively inhibits NF-kappaB activation in rat hepatocytes. Shock. 18: 182-188.
324. Flegel, W. A., A. Wolpl, D. N. Mannel, and H. Northoff. 1989. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect. Immun. 57: 2237-2245.
325. Cavaillon, J. M., C. Fitting, N. Haeffner-Cavaillon, S. J. Kirsch, and H. S. Warren. 1990. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect. Immun. 58: 2375-2382.
326. Baumberger, C., R. J. Ulevitch, and J. M. Dayer. 1991. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology. 59: 378-383.
327. Weinstock, C., H. Ullrich, R. Hohe, A. Berg, M. W. Baumstark, I. Frey, H. Northoff, and W. A. Flegel. 1992. Low density lipoproteins inhibit endotoxin activation of monocytes. Arterioscler. Thromb. 12: 341-347.
328. Flegel, W. A., M. W. Baumstark, C. Weinstock, A. Berg, and H. Northoff. 1993. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect. Immun. 61: 5140-5146.
329. Kitchens, R. L., G. Wolfbauer, J. J. Albers, and R. S. Munford. 1999. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J. Biol. Chem. 274: 34116-34122.
330. Victorov, A. V., N. V. Medvedeva, E. M. Gladkaya, A. D. Morozkin, E. A. Podrez, V. A. Kosykh, and V. A. Yurkiv. 1989. Composition and structure of lipopolysaccharide-human plasma low density lipoprotein complex. Analytical ultracentrifugation, 31P-NMR, ESR and fluorescence spectroscopy studies. Biochim. Biophys. Acta. 984: 119-127.
331. Yan, J. J., J. S. Jung, J. E. Lee, J. Lee, S. O. Huh, H. S. Kim, K. C. Jung, J. Y. Cho, J. S. Nam, H. W. Suh, Y. H. Kim, and D. K. Song. 2004. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat. Med. 10: 161-167.
332. Park, C. T., and S. D. Wright. 1996. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J. Biol. Chem. 271: 18054-18060.
333. Wurfel, M. M., S. T. Kunitake, H. Lichenstein, J. P. Kane, and S. D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180: 1025-1035.
334. Vreugdenhil, A. C., A. M. Snoek, C. van't Veer, J. W. Greve, and W. A. Buurman. 2001. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J. Clin. Invest. 107: 225-234.
335. Vreugdenhil, A. C., C. H. Rousseau, T. Hartung, J. W. Greve, C. van't Veer, and W. A. Buurman. 2003. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 170: 1399-1405.
336. Vreugdenhil, A. C., M. A. Dentener, A. M. Snoek, J. W. Greve, and W. A. Buurman. 1999. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J. Immunol. 163: 2792-2798.
337. Dentener, M. A., A. C. Vreugdenhil, P. H. Hoet, J. H. Vernooy, F. H. Nieman, D. Heumann, Y. M. Janssen, W. A. Buurman, and E. F. Wouters. 2000. Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory tepe II epithelial cells: implications for local defense to bacterial endotoxins. Am. J. Respir. Cell Mol. Biol. 23: 146-153.
338. Jack, R. S., X. Fan, M. Bernheiden, G. Rune, M. Ehlers, A. Weber, G. Kirsch, R. Mentel, B. Furll, M. Freudenberg, G. Schmitz, F. Stelter, and C. Schutt. 1997. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature. 389: 742-745.
339. Lamping, N., R. Dettmer, N. W. Schroder, D. Pfeil, W. Hallatschek, R. Burger, and R. R. Schumann. 1998. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J. Clin. Invest. 101: 2065-2071.
340. Hailman, E., J. J. Albers, G. Wolfbauer, A. Y. Tu, and S. D. Wright. 1996. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J. Biol. Chem. 271: 12172-12178.
341. Recalde, D., M. A. Ostos, E. Badell, A. L. Garcia-Otin, J. Pidoux, G. Castro, M. M. Zakin, and D. Scott-Algara. 2004. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler. Thromb. Vasc. Biol. 24: 756-761.
342. Van Oosten, M., P. C. Rensen, E. S. Van Amersfoort, M. Van Eck, A. M. Van Dam, J. J. Breve, T. Vogel, A. Panet, T. J. Van Berkel, and J. Kuiper. 2001. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J. Biol. Chem. 276: 8820-8824.
343. de Bont, N., M. G. Netea, P. N. Demacker, I. Verschueren, B. J. Kullberg, K. W. van Dijk, J. W. van der Meer, and A. F. Stalenhoef. 1999. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J. Lipid Res. 40: 680-685.
344. de Bont, N., M. G. Netea, P. N. Demacker, B. J. Kullberg, J. W. van der Meer, and A. F. Stalenhoef. 2000. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur. J. Clin. Invest. 30: 818-822.
345. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240: 622-630.
346. Allen, R. G., J. T. Barrett, and B. J. Campbell. 1971. Lipoprotein inhibitor of Newcastle disease virus from chicken lung. Appl. Microbiol. 21: 53-60.
347. Halonen, P. E., P. Toivanen, and T. Nikkari. 1974. Non-specific serum inhibitors of activity of haemagglutinins of rabies and vesicular stomatitis viruses. J. Gen. Virol. 22: 309-318.
348. Seganti, L., M. Grassi, P. Mastromarino, A. Pana, F. Superti, and N. Orsi. 1983. Activity of human serum lipoproteins on the infectivity of rhabdoviruses. Microbiologica. 6: 91-99.
349. Shortridge, K. F., W. K. Ho, A. Oya, and M. Kobayashi. 1975. Studies on the inhibitory activities of human serum lipoproteins for Japanese encephalitis virus. Southeast Asian J. Trop. Med. Public Health. 6: 461-466.
350. Shortridge, K. F., and W. K. Ho. 1976. Comparison of the activities in inhibition of haemagglutination by different togaviruses for human serum lipoproteins and their constituents. J. Gen. Virol. 33: 523-527.
351. Chisari, F. V., L. K. Curtiss, and F. C. Jensen. 1981. Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus. J. Clin. Invest. 68: 329-336.
352. Huemer, H. P., H. J. Menzel, D. Potratz, B. Brake, D. Falke, G. Utermann, and M. P. Dierich. 1988. Herpes simplex virus binds to human serum lipoprotein. Intervirology. 29: 68-76.
353. Srinivas, R. V., B. Birkedal, R.J. Owens, G. M. Anantharamaiah, J. P. Segrest, and R. W. Compans. 1990. Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology. 176: 48-57.
354. Owens, B. J., G. M. Anantharamaiah, J. B. Kahlon, R. V. Srinivas, R. W. Compans, and J. P. Segrest. 1990. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J. Clin. Invest. 86: 1142-1150.
355. Martin, I., M. C. Dubois, T. Saermark, and J. M. Ruysschaert. 1992. Apolipoprotein A-1 interacts with the N-terminal fusogenic domains of SIV (simian immunodeficiency virus) GP32 and HIV (human immunodeficiency virus) GP41: implications in viral entry. Biochem. Biophys. Res. Commun. 186: 95-101.
356. Kane, J. P., D. A. Hardman, J. C. Dimpfl, and J. A. Levy. 1979. Apolipoprotein is responsible for neutralization of xenotropic type C virus by mouse serum. Proc. Natl. Acad. Sci. USA. 76: 5957-5961.
357. Singh, I. P., A. K. Chopra, D. H. Coppenhaver, G. M. Ananatharamaiah, and S. Baron. 1999. Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res. 42: 211-218.
358. Ho, W. K. 1977. Serum lipoproteins as inhibitors of haemagglutination by rubella virus. Lipids. 12: 85-91.
359. Mastromarino, P., L. Seganti, and N. Orsi. 1980. Relationship between enzymatic modifications of serum low density lipoproteins and their haemagglutination inhibiting activity towards Sindbis virus. Arch. Virol. 65: 37-44.
360. Mastromarino, P., C. Conti, S. Rieti, and N. Orsi. 1988. Identification of lipid components of human serum lipoproteins involved in the inhibition of Sindbis virus infectivity, hemagglutination, and hemolysis. Arch. Virol. 103: 243-252.
361. Mastromarino, P., C. Conti, S. Rieti, and N. Orsi. 1989. Involvement of lipids in the interaction of Sindbis virus with goose erythrocytes. Microbiologica. 12: 113-120.
362. Karlsson, K. A. 1989. Animal glycosphingolipids as membrane attachment sites for bacteria. Annu. Rev. Biochem. 58: 309-350.
363. Fischer, D. G., N. Tal, D. Novick, S. Barak, and M. Rubinstein. 1993. An antiviral soluble form of the LDL receptor induced by interferon. Science. 262: 250-253.
364. Marlovits, T. C., T. Zechmeister, M. Gruenberger, B. Ronacher, H. Schwihla, and D. Blaas. 1998. Recombinant soluble low density lipoprotein receptor fragment inhibits minor group rhinovirus infection in vitro. FASEB J. 12: 695-703.
365. Marlovits, T. C., C. Abrahamsberg, and D. Blaas. 1998. Very-low-density lipoprotein receptor fragment shed from HeLa cells inhibits human rhinovirus infection. J. Virol. 72: 10246-10250.
366. Hofer, F., M. Gruenberger, H. Kowalski, H. Machat, M. Huettinger, E. Kuechler, and D. Blass. 1994. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci. USA. 91: 1839-1842.
367. Monazahian, M., I. Bohme, S. Bonk, A. Koch, C. Scholz, S. Grethe, and R. Thomssen. 1999. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57: 223-229.
368. Raper, J., R. Fung, J. Ghiso, V. Nussenzweig, and S. Tomlinson. 1999. Characterization of a novel trypanosome lytic factor from human serum. Infect. Immun. 67: 1910-1916.
369. Raper, J., M. P. Portela, E. Lugli, U. Frevert, and S. Tomlinson. 2001. Trypanosome lytic factors: novel mediators of human innate immunity. Curr. Opin. Microbiol. 4: 402-408.
370. Vanhamme, L., F. Paturiaux-Hanocq, P. Poelvoorde, D. P. Nolan, L. Lins, J. Van Den Abbeele, A. Pays, P. Tebabi, H. Van Xong, A. Jacquet, N. Moguilevsky, M. Dieu, J. P. Kane, P. De Baetselier, R. Brasseur, and E. Pays. 2003. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 422: 83-87.
371. Bout, D., M. Joseph, M. Pontet, H. Vorng, D. Deslee, and A. Capron. 1986. Rat resistance to schistosomiasis: platelet-mediated cytotoxicity induced by C-reactive protein. Science. 231: 153-156.
372. Xu, X., H. G. Remold, and J. P. Caulfield. 1993. Potential role for scavenger receptors of human monocytes in the killing of Schistosoma mansoni. Am. J. Pathol. 142: 685-689.
373. Sinnis, P., T. E. Willnow, M. R. Briones, J. Herz, and V. Nussenzweig. 1996. Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes. J. Exp. Med. 184: 945-954.
374. Walton, K. A., A. L. Cole, M. Yeh, G. Subbanagounder, S. R. Krutzik, R. L. Modlin Medlin, R. M. Lucas, J. Nakai, E. J. Smart, D. K. Vora, and J. A. Berliner. 2003. Specific phospholipid oxidation products inhibit ligand activation of Toll-like receptors 4 and 2. Arterioscler. Thromb. Vasc. Biol. 23: 1197-1203.
375. Bochkov, V. N., A. Kadl, J. Huber, F. Gruber, B. R. Binder, and N. Leitinger. 2002. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature. 419: 77-81.
376. Hauton, D., and R. D. Evans. 2002. Utilisation of fatty acid and triacylglycerol by rat macrophages: the effect of endotoxin. Cell. Physiol. Biochem. 12: 293-304.
377. Kisilevsky, R., and L. Subrahmanyan. 1992. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab. Invest. 66: 778-785.
378. Tietge, U. J., C. Maugeais, W. Cain, and D. J. Rader. 2003. Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. Am. J. Physiol. Endocrinol. Metab. 285: E403-E411.
379. Cuthbert, J. A., and P. E. Lipsky. 1987. Regulation of lymphocyte proliferation by cholesterol: the role of endogenous sterol metabolism and low density lipoprotein receptors. Int. J. Tissue React. 9: 447-457.